Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-07-18
2006-07-18
Kaushal, Sumesh (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S093200, C424S484000, C435S069100, C435S320100, C435S325000, C435S455000
Reexamination Certificate
active
07078032
ABSTRACT:
Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin™, interferons, and anti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells. Matrices can be formed of synthetic or natural materials, by chemical coupling at the time of implantation, using standard techniques for formation of fibrous matrices from polymeric fibers, and using micromachining or microfabrication techniques. These devices and strategies are used as delivery systems via standard or minimally invasive implantation techniques for any number of parenterally deliverable recombinant proteins, particularly those that are difficult to produce in large amounts and/or active forms using conventional methods of purification, for the treatment of a variety of conditions.
REFERENCES:
patent: 4404199 (1983-09-01), Bonaldi et al.
patent: 4487833 (1984-12-01), Donahoe et al.
patent: 4510131 (1985-04-01), Donahoe et al.
patent: 4753794 (1988-06-01), Donahoe
patent: 4792601 (1988-12-01), Donahoe et al.
patent: 5011687 (1991-04-01), Donahoe et al.
patent: 5047336 (1991-09-01), Cate et al.
patent: 5198420 (1993-03-01), Donahoe et al.
patent: 5204055 (1993-04-01), Sachs et al.
patent: 5661126 (1997-08-01), Donahoe et al.
patent: 5709854 (1998-01-01), Griffith-Cima et al.
patent: 5759830 (1998-06-01), Vacanti et al.
patent: 6149907 (2000-11-01), Selawry
patent: 6692738 (2004-02-01), MacLaughlin et al.
patent: WO 93/17669 (1993-09-01), None
patent: WO 94/00133 (1994-01-01), None
patent: WO 94/25080 (1994-11-01), None
patent: WO 96/40002 (1996-12-01), None
Epstein et al In Vitro Cell Dev Biol. 25(2):213-216, 1989.
Amalfitano and Parks, “Separating Fact from Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy”, Current Gene Therapy, 2002, 2, 111-133.
Bogden, et al., “Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice,” Exp Cell Biol 47(4): 281-93 (1979).
Boveri, et al., “Transfection of the Mullerian inhibiting substance gene inhibits local and metastic tumor growth,” Int J. Oncology 2: 135-44 (1993).
Budzik, et al., “Mullerian inhibiting substance fractionation by dye affinity chromatography,” Cell 34: 307-314 (1983).
Cao et al., “Expression of angiostatin cDNA in a murine fibrosarcoma supresses primary tumor growth and produces long-term dormancy of metastases” J. Clin. Invest., vol. 101, No. 5, Mar. 5, 1998, pp. 1055-1063.
Cate, et al., “Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells,” Cell 45: 685-98 (1986).
Chamberlain, et al., “Early peripheral nerve healing in collagen and silicone tube implants:myofibroblasts and the cellular response,” Biomaterials 19(15): 1393-1403 (1998).
Chin, et al., “Human mullerian inhibiting substance inhibits tumor growth in vitro and in vivo,” Cancer Research 51: 2101-2106 (1991).
Donahoe, et al., “A graded organ culture assay for the detection of Mullerian inhibiting substance,” J Surg Res 23: 141-8 (1977).
Donahoe, et al., “Mullerian duct regression in the embryo correlated with cytotoxic activity against human ovarian cancer,” Science 205: 913-5 (1979).
Donahoe, et al., “Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice,” Ann Surgery 194: 472-80 (1981).
Fingert, et al., “Rapid growth of human cancer cells in a mouse model with fibrin clot subrenal capsule assay,” Cancer Res. 47: 3824-3829 (1987).
Fuller, et al., “Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line,” J Clin Endocr Metab. 54: 1051-5 (1982).
Fuller, et al., “Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay,” Gynecol. Oncol. 22: 135-148 (1985).
Gilbert et al., “Cell transportation of genetically altered cells on biodegradable polymer scaffolds in syngeneic rats,” Transplantation, vol. 56, Aug. 2, 1998,pp. 423-427.
Gustafson, et al., “Mullerian inhibiting substance as a marker for ovarian sex-cord tumor,” N. Eng. J. Med. 326(7): 466-471 (1992).
Hadlock, et al., “A novel, biodegradable polymer conduit delivers neurotrophins and promotes nerve regeneration,”Laryngoscope 109(9): 1412-1416 (1999).
Hudson, et al., “An immunoassay to detect human mullerian inhibiting substance in males and females during normal development,” J Clin Endocrinol Metab. 70:16-22 (1990).
Krist Jansen, et al., “Tissue-isolated human tumor xenografts in athymic nude mice,” Microvasc. Res. 48: 389-402 (1994).
Kurian, et at., “Cleavage of Mullerian inhibiting substance activates antiproliferative effects in vivo,” Clin. Cancer Res. 1(3): 343-349 (1995).
Lee, et al., “Mullerian inhibiting substance in humans: normal levels from infancy to adulthood,” J Clin Endocrinol Metab. 81: 571-69 (1996).
Li and Ma, “Nonviral Gene Therapy,” Current Gene Therapy, 2001, 1, 201-226.
Lorenzo et al . . . , “New Approaches for High-Yield Purification of Mullerian Inhibiting Substance Improve Its Bioactivity” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 766, Issue 1, pp. 89-98 (2002).
MacLaughlin, et al., “Bioassay, purification, cloning and expression of Mullerian inhibiting substance,” Methods Enzymol. 198: 358-69 (1991).
MacLauglin, et al., “Mullerian duet regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain,” Endocrinology 131(1): 291-6 (1992).
Masiakos, et al., “Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS,” Clinical Cancer Research 5(11): 3488-99 (1999).
Matsuda, et al., “Photoinduced prevention of tissue adhesion,” ASAIO Trans. 38: 154-157 (1992).
O'Reilly, et al., “Antiangiogenic activity o the cleaved conformation of the serpin antithrombin,” Science 285(5435): 1926-8 (1999).
Parry, et al., “Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo,” Cancer Res. 52: 1182-6 (19892).
Pepinsky, et al., “Proteolytic processing of mullerian inhibiting substance produces a transforming growth factor-beta-like fragment,” J. Biol. Chem. 263: 18961-41 (988).
Qin et al., “Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice,” Proc. Natl. Acad. Sci. USA, vol. 95, Nov. 1998, pp. 14411-14416.
Ragin, et al., “Human mullerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects,” Protein Expression and Purification 3(3): 236-45 (1992).
Segev et al . . . , “Mullerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NFkB-mediated Pathway” Journal of Biological Ch
Donahoe Patricia K.
MacLaughlin David T.
Masiakos Peter T.
Vacanti Joseph P.
Edwards Angell Palmer & & Dodge LLP
Kaushal Sumesh
Leahy Amy M.
The General Hospital Corporation
LandOfFree
Delivery of therapeutic biologicals from implantable tissue... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Delivery of therapeutic biologicals from implantable tissue..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delivery of therapeutic biologicals from implantable tissue... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3548714